PORTLAND, Ore.--(BUSINESS WIRE)--Calypte Biomedical Corporation (OTCBB: CBMC), a developer, manufacturer and marketer of HIV diagnostic tests, announced today that its Beijing China manufacturing subsidiary, Beijing Marr Bio-pharmaceutical Co., Ltd., Beijing China, a joint venture between Calypte and a Marr Group subsidiary (“Marr”) has successfully passed its quality system audit and obtained certification of its quality system to the international standard, ISO 13485:2003. Certification was provided by TÜV SÜD Management Service GmbH of Munich Germany.
